

State of Oklahoma SoonerCare



Amtagvi™ (Lifileucel) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
) □ Pharmacy billing (NDC:)	
Dose:Regimen:		e (or date of next dose):
	Billing Provider Informati	
	Provider Name:	
Provider Phone:Provider Fax: Prescriber Information		
Prescriber NPI:		Specialty:
rrescriber rilone	Criteria	Specially
request. Is this information atta 2. Please indicate the diagnosis Melanoma A. Is diagnosis unresed B. Was member previo C. Is disease BRAF V6 i. If yes, was mem inhibitor? Yes D. Will lifileucel be adm and specialists skille	ached? Yes No and information: ctable or metastatic melanoma? No usly treated with a PD-1 inhibitor 00 mutation positive? Yes No ber previously treated with a BRA No inistered in an inpatient hospital of the cardiopulmonary or intensive the control of the cardiopulmonary or intensive the cardiopulmonary or intensi	? Yes No No AF inhibitor with or without a MEK setting with an intensive care facility e care medicine available?
Prescriber Signature:	Dat	te:

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 263 4/4/2024